MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag192

Медицинская библиотека · The oncologist · 2026

Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study.

Yan Yu, Liu Xiaoyan, Du Yang, Dou Qiqi, Wang Hanping, Si Xiaoyan, Zhang Xiaotong, Wu Xuefei, Zhou Yunzhi, Li Mei, Zhong Wei, Wang Mengzhao, Zhang Li

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Neoplastic fever (NF) severely impairs quality of life and often limits antitumor therapy, yet effective treatment remains lacking. Given the central role of interleukin-6 (IL-6), we evaluated tocilizumab for NF management.

METHODS

We retrospectively reviewed NF cases at 3 Chinese hospitals (2019-2023). Patients who received tocilizumab and had evaluable follow-up data were included in analyses of fever resolution, afebrile duration, Karnofsky Performance Status, inflammatory markers, antitumor outcomes, and adverse events (AEs). In patients with sequential exposure to non-steroidal anti-inflammatory drugs (NSAIDs) and tocilizumab, changes in inflammatory markers after each treatment were compared.

RESULTS

Forty-five patients were identified (median age 65). All had elevated CRP and IL-6. Among 22 treated with tocilizumab, all achieved fever resolution within 24 hours, sustained for ≥2 weeks, with significant reductions in CRP (mean, 95.7-19.0 mg/L) and other inflammatory markers. Median afebrile duration was 3 weeks, extended to 4 weeks with re-treatment. Systemic therapy was subsequently administered in patients with poor baseline performance, who achieved an objective response rate of 50%, a median progression-free survival of 11.6 months, and an overall survival of 21.3 months. AEs occurred in 81.8% (grade ≥3, 31.8%) but were manageable. Compared with NSAIDs, tocilizumab uniquely improved anemia and inflammatory control.

CONCLUSION

Tocilizumab provided rapid and durable fever resolution with systemic anti-inflammatory effects, accompanied by functional and hematologic improvement. These findings suggest IL-6 blockade as a promising therapeutic option for NF.

Для цитирования: Yan Yu, Liu Xiaoyan, Du Yang, Dou Qiqi, Wang Hanping, Si Xiaoyan, Zhang Xiaotong, Wu Xuefei, Zhou Yunzhi, Li Mei, Zhong Wei, Wang Mengzhao, Zhang Li. Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag192.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.